In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alberto-Culver sales up 4.5% to $445.4 mil. in first quarter in "tough" environment.

This article was originally published in The Rose Sheet

Executive Summary

ALBERTO-CULVER NET SALES UP 4.5% TO $445.4 MIL. in the first quarter of fiscal 1998 (ended Dec. 31) compared to sales of $426.1 mil. in the same quarter of FY 1997, Alberto-Culver announced Jan. 22. The company attributed a major portion of its growth to the Sally Beauty Company division, which reported a double-digit sales increase. Net earnings rose 17.4% to $19.7 mil. from $16.8 mil. in the year-ago quarter, excluding an after-tax gain of $9.8 mil. in FY 1997 related to an insurance payment following the crash of a corporate airplane. The "increases were achieved in a tough competitive environment and in the face of material impact from lower currency rates internationally," President and CEO Howard Bernick observed at a same-day annual shareholders meeting.

You may also be interested in...



OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands

Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle

Chart: Weekly Trademark Review -- Nov. 2, 2010

Weekly Trademark Review
UsernamePublicRestriction

Register

RS005063

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel